pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Big Pharma · news · pharmadog
← back to Big Pharma
News · Big Pharma
309
stories
Sep 28, 26
AbbVie wins FDA approval for Parkinson’s drug from $8.7B Cerevel takeover
biospace
Sep 28, 26
6 immunology targets to sustain a mammoth I&I market
biospace
Sep 25, 26
Nektar prevails in legal battle with Lilly over broken rezpeg partnership
biospace
Sep 25, 26
Adicet Bio CAR-T sparks lupus remissions in early trial as ‘new era’ of autoimmune treatment approaches
fiercebiotech
Sep 25, 26
Novo inks $1.3B Nanexa deal to unlock long-acting obesity injectables
fiercebiotech
Sep 24, 26
Roche inks up to $2B deal with Atavistik for new cardiometabolic drugs
biospace
Sep 24, 26
Merck sees pivotal victory for $3B eye disease prospect
fiercebiotech
Sep 23, 26
Kyverna ‘resetting conversation’ with 1-year miv-cel data as autoimmune CAR-T peers hit safety snags
fiercebiotech
Sep 22, 26
GSK aiming to ‘balance West and East’ after Hansoh deal success showed China’s potential
fiercebiotech
Sep 22, 26
Deep Dive: How AI is now essential in biopharma
biospace
Sep 22, 26
Iambic maintains momentum from string of Big Pharma partnerships by aiming for IPO
fiercebiotech
Sep 21, 26
Retension and Lilly-backed TRex Bio both set out plans to join biotech IPO stampede
fiercebiotech
Sep 18, 26
BMS scraps Orum’s targeted degrader after reviewing Phase 1 data
biospace
Sep 18, 26
BMS dumps $100M Orum degrader-antibody conjugate after glimpsing phase 1 data
fiercebiotech
Sep 17, 26
Chutes & Ladders—Legend poaches Novartis vet to boost commercial potential
fiercebiotech
Sep 17, 26
Fed rate hike won’t hold biotech down despite climbing capital costs
biospace
Sep 17, 26
After Novartis’ devastating M&A losses, long live the executive willing to try
biospace
Sep 17, 26
Novartis drops $125M for Sironax’s tech to cross blood-brain barrier
biospace
Sep 17, 26
Roche signs $1B deal with Dualitas to pair up on big bispecific screening drive
fiercebiotech
Sep 16, 26
Novo looks to Anthropic’s AI models to ‘supercharge’ drug development
biopharma dive
Sep 16, 26
Deep dive: Psychedelics back on FDA’s doorstep
biospace
Sep 16, 26
Novo explores macrocycles’ potential in $1.4B cardiometabolic pact with Danish biotech
fiercebiotech
Sep 16, 26
5 biotechs braving the commercial waters with product launches
biospace
Sep 15, 26
Lilly pledges up to $237M per program in CNS genetic med collab with Canadian biotech
fiercebiotech
Sep 15, 26
GSK doubles down on Chimagen with $750M multiple myeloma wager
fiercebiotech
Sep 15, 26
J&J’s Contineum-partnered depression drug flunks another phase 2 test
fiercebiotech
Sep 14, 26
No more Nordisk as Novo goes it alone amid rebranding push
fiercebiotech
Sep 14, 26
Cellectis cans allogeneic CAR-Ts to hop aboard in vivo bandwagon
fiercebiotech
Sep 14, 26
Psychedelic therapies ride wave of public favor into FDA hearing
biospace
Sep 11, 26
This week in charts: RA’s insatiable appetite, Novartis’ big slide and a reverse merger spree
biopharma dive
← prev
page 6 of 11
next →